Reported by Huang Wen-Chi from Boston

Dr Wu Tsung-Tsong, the Minister without Portfolio of the Executive Yuan, is now leading the Team of Taiwan to attend the Bio 2018 in Boston.  From Boston, Dr Wu revealed that the Financial Supervisory Commission (FSC) has been working on speeding up the assessment of the listing applications filed by biomedical startups with a view to attracting more international investment in the biotech industry in Taiwan.  Dr Wu expressed that the reform will be so significant that the industry will feel the change.

According to Dr Wu, the missions of the Team are to attract international biomedical companies to list in the stock market in Taiwan, to promote the Taiwan Bio Bank established by Academia Sinica, and to pitch the accelerator created by the Development Center for Biotechnology (DCB) at international capitalists.

Regarding precision medicine and smart medicine, Dr Wu pointed out that the Taiwan Bio Bank integrates 19 hospital databanks and links to the NHI database, creating a big data set which will empower the biomedical industry in Taiwan to attract more international partners.

Dr Wu expressed that there have been many collaboration projects between the industry and the academia.  The development of international accelerator will further facilitate the collaboration between the end-users (physicians) and the developers.  This will give Taiwan an advantage.

Dr Wu continued that the FSC’s purpose of attending the Bio 2018 is to attract investment, hoping international companies would join the capital market in Taiwan.  To achieve this mission, he accompanied the Team to attend the conference in Boston and held the Taiwan Bio Forum in Harvard Medical School to promote the biotech industry in Taiwan.

【2018-06-05/ Economic Daily】